Does FAM-TRASTUZUMAB DERUXTECAN-NXKI Cause Hepatic function abnormal? 38 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 38 reports of Hepatic function abnormal have been filed in association with FAM-TRASTUZUMAB DERUXTECAN-NXKI. This represents 0.5% of all adverse event reports for FAM-TRASTUZUMAB DERUXTECAN-NXKI.
38
Reports of Hepatic function abnormal with FAM-TRASTUZUMAB DERUXTECAN-NXKI
0.5%
of all FAM-TRASTUZUMAB DERUXTECAN-NXKI reports
16
Deaths
19
Hospitalizations
How Dangerous Is Hepatic function abnormal From FAM-TRASTUZUMAB DERUXTECAN-NXKI?
Of the 38 reports, 16 (42.1%) resulted in death, 19 (50.0%) required hospitalization, and 1 (2.6%) were considered life-threatening.
Is Hepatic function abnormal Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for FAM-TRASTUZUMAB DERUXTECAN-NXKI. However, 38 reports have been filed with the FAERS database.
What Other Side Effects Does FAM-TRASTUZUMAB DERUXTECAN-NXKI Cause?
Nausea (1,037)
Interstitial lung disease (880)
Disease progression (794)
Death (717)
Fatigue (652)
Off label use (651)
Vomiting (464)
Diarrhoea (463)
Pneumonitis (337)
No adverse event (315)
What Other Drugs Cause Hepatic function abnormal?
NIVOLUMAB (1,131)
PEMBROLIZUMAB (1,079)
METHOTREXATE (1,054)
CABOZANTINIB S-MALATE (912)
CYCLOPHOSPHAMIDE (824)
BEVACIZUMAB (769)
PACLITAXEL (603)
LENVATINIB (528)
ATORVASTATIN (520)
CYCLOSPORINE (508)
Which FAM-TRASTUZUMAB DERUXTECAN-NXKI Alternatives Have Lower Hepatic function abnormal Risk?
FAM-TRASTUZUMAB DERUXTECAN-NXKI vs FAMCICLOVIR
FAM-TRASTUZUMAB DERUXTECAN-NXKI vs FAMOTIDINE
FAM-TRASTUZUMAB DERUXTECAN-NXKI vs FAMOTIDINE\IBUPROFEN
FAM-TRASTUZUMAB DERUXTECAN-NXKI vs FARICIMAB
FAM-TRASTUZUMAB DERUXTECAN-NXKI vs FARICIMAB-SVOA